This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Renal cancer	Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1); von Hippel-Lindau tumor suppressor (vHL)	<i>In vitro</i> and mouse studies identified small molecule inhibitors of GLUT1 that could help treat renal cell carcinoma (RCC). In RCC cells, the GLUT1 inhibitor STF-31 lowered glucose uptake, inhibited glycolysis and increased cell death compared with vehicle. In mice with RCC xenografts, an analog of STF-31 delayed tumor growth compared with vehicle. Ruga Corp.'s next steps include optimizing the lead compound. SciBX 4(32); doi:10.1038/scibx.2011.907 Published online Aug. 18, 2011	Patented; exclusively licensed to Ruga	Chan, D.A. <i>et al. Sci. Transl. Med.</i> ; published online Aug. 3, 2011; doi:10.1126/scitranslmed.3002394 Contact: Amato J. Giaccia, Stanford University School of Medicine, Stanford, Calif. e-mail: giaccia@stanford.edu